Philadelphia Eagles quarterback Jalen Hurts will miss Sunday’s game against the Carolina Panthers after a follow-up ultrasound showed movement in a previously detected superficial blood clot in his leg. The team is evaluating treatment options, and no timetable for his return has been announced.
Hurts was ruled out of the October 18 matchup after the Philadelphia Eagles announced on October 15 that a follow-up medical examination had revealed movement in the small blood clot. The finding came several days after doctors initially detected the clot while evaluating a calf injury he sustained during the team’s October 4 game against the Los Angeles Rams.
The development has drawn attention to a medical condition that can range from relatively minor inflammation in a vein near the skin to a potentially serious circulation problem. Although superficial blood clots are generally considered less dangerous than clots in the body’s deeper veins, their location, size, extent and risk of progression can influence how doctors manage them.
The Eagles said their immediate priority is Hurts’ health and safety as the medical staff determines the appropriate course of treatment. The team has not publicly disclosed the precise dimensions of the clot, the specific treatment being considered or when the quarterback might be cleared to return.
According to the team’s account, Hurts first visited the training room after practice on October 8 to seek treatment for his calf. He told medical staff that he had been struck by an opponent’s cleat during Philadelphia’s loss to the Rams four days earlier. He had participated fully in practices on Wednesday and Thursday before seeking treatment and subsequently continued practicing.
Hurts was added to the injury report on October 9. The following day, after the Eagles traveled to London for their game against the Jacksonville Jaguars, the medical staff arranged an ultrasound as a precaution. The examination identified a superficial blood clot.
Doctors in London reviewed the results and determined that Hurts could safely play against Jacksonville. According to the Eagles, the medical team also recommended another ultrasound within 72 hours of the game and the return flight to Philadelphia.
Hurts played without restrictions in London’s October 11 game, which Philadelphia lost 19-17 to the Jaguars. He received treatment on Monday and Tuesday and participated fully in Wednesday’s practice, according to the team’s statement.
A follow-up ultrasound on Wednesday night, October 14, showed movement in the small clot. The finding prompted the team to rule him out of the Panthers game while it assesses the next steps in his care.
Backup quarterback Tanner McKee is expected to start in Hurts’ absence. However, the immediate sporting consequence is secondary to the medical question facing the Eagles: how to manage the clot safely and determine when Hurts can resume football activities.
What a Superficial Blood Clot Means
Blood clotting is a normal and essential process that helps stop bleeding after an injury. Platelets and proteins in the blood work together to form a clot, allowing the body to limit blood loss and begin healing. Problems arise when clots develop inside blood vessels where they obstruct normal circulation or when a clot extends into a more dangerous area.
A superficial blood clot, medically described as superficial venous thrombosis, forms in a vein close to the surface of the skin. These veins are found in areas such as the legs and arms. The condition can cause inflammation, tenderness, redness, warmth and swelling around the affected vein.
Superficial venous thrombosis is different from deep vein thrombosis, commonly known as DVT. A DVT develops in a deeper vein, often in the calf, thigh or pelvis. Deep vein clots can become dangerous if part of the clot breaks away, travels through the bloodstream and blocks an artery in the lungs. This complication is called a pulmonary embolism and can be life-threatening.
The distinction is important in Hurts’ case. The Eagles have described his diagnosis as a superficial blood clot, but the follow-up scan showed movement within the clot. The team has not said publicly that the clot entered a deep vein or traveled to another part of his body. Movement on an ultrasound should not, by itself, be interpreted as proof that either complication has occurred.
Nevertheless, a change in a clot’s position or appearance can lead doctors to reassess its location, extent and potential risks. Superficial clots can sometimes extend into the deep venous system, and some patients with superficial venous thrombosis also have a DVT. That is why medical evaluation and appropriate follow-up are important, even when the original diagnosis involves a superficial vein.
Ultrasound is an important tool in this process. It uses sound waves to create images of structures inside the body and can help clinicians identify a clot, assess the affected vein and determine whether deeper veins are involved. The findings are considered alongside a patient’s symptoms, medical history and other risk factors before a treatment decision is made.
The publicly available information about Hurts does not establish why his clot developed beyond the team’s account of the preceding calf injury. Physical trauma can contribute to clot formation, but blood clots may have multiple contributing factors, and an individual cause cannot be confirmed from the diagnosis alone.
Prolonged periods of limited movement, including during long-distance travel, are also recognized risk factors for certain types of blood clots. Other factors may include recent surgery, a previous clot, some cancers, inherited or acquired clotting disorders, varicose veins and certain hormone treatments. These are general risk factors, not evidence that any particular factor caused Hurts’ condition.
Symptoms, Diagnosis and Treatment
Symptoms of a superficial blood clot can include pain or tenderness along a vein, localized swelling, redness or darker skin discoloration, and an area of skin that feels unusually warm. In some cases, the affected vein may feel firm or form a tender cord beneath the skin. Symptoms can vary depending on the clot’s location and extent.
Persistent or worsening leg pain, new swelling, warmth or redness should be assessed by a healthcare professional because symptoms of superficial thrombosis can overlap with those of DVT. An examination and ultrasound may be needed to distinguish between the conditions and determine whether further testing or treatment is appropriate.
Emergency warning signs include sudden shortness of breath, chest pain that may worsen with a deep breath, coughing up blood, a rapid heartbeat or fainting. These symptoms can indicate a pulmonary embolism or another serious medical problem and require immediate emergency medical attention.
Treatment depends on the nature of the clot and the patient’s overall risk. A small superficial clot may be managed with measures to relieve discomfort and inflammation, such as warm compresses, elevation of the affected limb or other clinician-recommended care. Compression garments may be appropriate for some patients, depending on the location of the clot and medical advice.
In other cases, doctors may prescribe anticoagulant medication, commonly called a blood thinner, to reduce the risk of a clot growing or additional clots forming. The decision can depend on factors such as the clot’s length, location, proximity to deeper veins, symptoms and the patient’s medical history. Superficial thrombosis does not automatically require the same treatment as a DVT.
Deep vein thrombosis is generally treated with anticoagulants to prevent the clot from enlarging and reduce the likelihood of further clot formation. These medicines do not instantly remove an existing clot; instead, they help prevent complications while the body’s natural processes gradually break down the clot. More intensive treatments may be considered for selected patients with severe or complicated clots.
Anticoagulants also carry risks, particularly bleeding, so they must be prescribed and managed according to an individual’s medical circumstances. Patients should not attempt to treat a suspected blood clot themselves or start, stop or change blood-thinning medication without medical guidance.
For Hurts, the next step is to follow the team’s medical assessment and treatment plan. His ability to practice fully before the follow-up scan does not, on its own, determine whether returning to the field would be safe. The decision must account for the clot’s condition and the risks associated with intense physical activity and potential contact during a football game.
The Eagles have not provided a return date, and the latest public statement does not establish whether Hurts will miss games beyond the Carolina matchup. His availability will depend on the medical staff’s assessment and any subsequent updates from the team.
The case also illustrates why a blood clot’s classification matters but does not tell the whole story. A superficial clot is generally less serious than a deep vein clot, yet its location and behavior can warrant careful monitoring. In Hurts’ situation, the decision to sit out Sunday’s game followed a new finding on follow-up imaging, underscoring the importance of reassessment when a clot changes.
For the Eagles, the immediate focus is managing the condition safely rather than setting a return deadline. Until the team releases further information, the extent of the clot, the treatment selected and the timing of Hurts’ return remain uncertain.